| dc.creator |
Karacik, Mert |
|
| dc.creator |
EVRANOS AKSÖZ, Begüm |
|
| dc.date |
2025-01-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:40:20Z |
|
| dc.date.available |
2025-02-25T10:40:20Z |
|
| dc.identifier |
e37f4e95-6586-4673-91f9-94b357c9964b |
|
| dc.identifier |
10.33483/jfpau.1487644 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/e37f4e95-6586-4673-91f9-94b357c9964b/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/101706 |
|
| dc.description |
Objective: Depression is a psychiatric illness that can occur at any time of a person's life. Antidepressants are medications used in the first-line treatment of depression. Treatment of depression with antidepressants can be unfavorable due to the long duration of treatment, the development of resistance to treatment and the occurrence of side effects in the patient after taking antidepressants. Improvements to existing antidepressants are essential to increase the success rate of treatment. Result and Discussion: One of the aims of drug research and development is to ensure more efficient use of drugs. When the antidepressants approved by the FDA in the last 11 years are analyzed, it is seen that most of the studies were carried out by preparing different dosage forms of previously developed drugs, using a specific isomer or developing allopregnanolone-like substances, which is a steroidal neuroactive substance. |
|
| dc.language |
tur |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
FDA APPROVED ANTIDEPRESSANTS AND NEW ANTIDEPRESSANT DRUG DEVELOPMENT STUDIES BETWEEN 2013-2024 2013-2024 YILLARI ARASINDA FDA ONAYI ALMIŞ ANTİDEPRESANLAR VE YENİ ANTİDEPRESAN İLAÇ GELİŞTİRME ÇALIŞMALARI |
|
| dc.type |
info:eu-repo/semantics/article |
|